Novo Nordisk and Pfizer have escalated their competing bids for obesity drug developer Metsera to approximately $10 billion, transforming what began as a straightforward acquisition into a high-stakes corporate battle marked by legal challenges and regulatory scrutiny. Metsera’s board declared
“We really have a tough target of cutting emissions by 50% by 2030—we need to understand the right path with our suppliers” Nataša Vidmar, SVP and Chief Procurement Officer at AstraZeneca, delivered a clear message at the PSCI Decarbonization Summit:
Pfizer Inc. has entered into a definitive agreement to acquire Metsera Inc., a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases, for approximately $4.9 billion. The deal, unanimously approved by the Boards of Directors of both companies, includes a
Pfizer is prepared to adapt if pharmaceutical tariffs are introduced under a second Trump administration, CEO Albert Bourla, Ph.D., said at TD Cowen’s 45th annual healthcare conference in Boston. The company already operates 13 manufacturing sites across the U.S. and could
Fred Turco is Vice President of Enterprise Indirects and Sustainable Sourcing Lead at Pfizer. He explains how the company is making progress towards Net Zero by collaborating with suppliers.
